NCT04467684View on ClinicalTrials.gov

Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406

PHASE1CompletedINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

May 30, 2021

Study Completion Date

June 6, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

CB-0406 100 mg

Single oral dose

DRUG

CB-0406 200 mg

Single oral dose

DRUG

CB-0406 400 mg

Single oral dose

DRUG

CB-0406 800 mg

Single oral dose

DRUG

CB-0406 1,000 mg

Single oral dose

DRUG

Matched placebo

Color and size matched placebo

Trial Locations (1)

3181

Nucleus Network, Melbourne

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT04467684 - Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406 | Biotech Hunter | Biotech Hunter